Insider · CIK 0001779269
James J. Collins
Files at SNTI (Senti Biosciences, Inc.). First filing -, latest -.
James J. Collins files SEC Form 4 as director at SNTI (Senti Biosciences, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; James J. Collins has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 25, 2025 | SNTI Senti Biosciences, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +21,950 | $0.00 | $0 | 21,950 | Jun 27, 2025 |
| Mar 7, 2025 | SNTI Senti Biosciences, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +43,900 | $0.00 | $0 | 43,900 | Mar 11, 2025 |
Questions about James J. Collins
Answered from the filings on this page, as of the latest one.
Is James J. Collins buying or selling?
James J. Collins has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did James J. Collins's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and James J. Collins has 0.
Where does James J. Collins file Form 4?
James J. Collins has filed Form 4 at SNTI (Senti Biosciences, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.